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Letter to the EditorPrenatal phthalate and early childhood bisphe-
nol A exposures increase asthma risk in inner-
city children
To the Editor:
We previously reported that inner-city childhood asthma was
independently associated with measures of early childhood
exposure to bisphenol A (BPA)1 and prenatal, but not childhood,
exposures to di-n-butyl phthalate and butylbenzyl phthalate
(BBzP).2 Here, we evaluate whether these 2 classes of endocrine-
disrupting chemicals interact to increase the risk of asthma.
We evaluated 292 inner-city women and their children aged 5
to 11 years from the Columbia Center for Children’s Environ-
mental Health birth cohort of pregnant women who delivered
between 1998 and 2006. Enrollment, exclusion criteria, and a
description of the cohort have been reported previously.3 Subjects
were selected for the present study on the basis of the availability
of (1) measurements of phthalates in spot urine collected from the
mother during pregnancy (33.96 3.1 weeks’ gestation) and BPA
in child urine at ages 3 (n 5 237), 5 (259), and/or 7 (n 5 161)
years; (2) data on child asthma and wheeze-related outcomes;
and (3) availability of model covariates. Demographic character-
istics of Columbia Center for Children’s Environmental Health
subjects are provided in Table E1 in this article’s Online
Repository at www.jacionline.org. All participants gave written
informed consent.
Samples were analyzed at the Centers for Disease Control and
Prevention for concentrations of monobenzyl phthalate (MBzP,
metabolite of BBzP), mono-n-butyl phthalate (MnBP, metabolite
of di-n-butyl phthalate), and BPA.4,5 Consistent with our previous
approach,1 mean urinary postnatal BPA concentrations were
calculated across samples of children aged 3 to 7 years, except
for a small subset (n 5 10) missing respiratory questionnaire
data after age 6 years for whom the mean BPA was calculated
for ages 3 to 5 years. Specific gravity was measured using a hand-
held refractometer (Atago PAL 10-S, Bellevue, Wash) to control
for urinary dilution.
Repeat questionnaires, including the International Study of
Asthma and Allergies in Childhood, were administered to the
parent at child ages 5, 6 7, 9, and 11 years (n 5 1202
questionnaires, average 4.1 per child). Children with report in
the last 12 months of any of the following asthma-related
symptoms on 1 or more questionnaire were referred to an allergist
or a pulmonologist for asthma diagnosis using standardized
criteria: wheeze or whistling in the chest, a cough that lasted
more than a week, other breathing problems, and/or use of asthma
rescue or controller medication.1 Children without any of these
asthma-related symptoms on the repeat questionnaires were clas-
sified as nonasthmatic. Children were evaluated for persistent
wheeze (>_ 3 reports of wheeze in the last 12 months on >_ 3 Inter-
national Study of Asthma and Allergies in Childhood question-
naires), exercise-induced wheeze (>_ 1 report in the last 12
months of the child’s chest sounding wheezy during or after exer-
cise), and report of emergency care visits in the last 12months to a
doctor, clinic, or emergency room for asthma, wheeze, or other
breathing problems on 1 or more repeat questionnaire.
Variables assessed as potential confounders have been
described1,2 and were retained in the models if they weresignificant (P < .05) and/or their inclusion resulted in more than
10% change in the predictor variables (see this article’s Online
Repository at www.jacionline.org). Before statistical analyses,
the 1 prenatal MBzP and 15 postnatal BPA concentrations below
the limit of detection (0.22 mg/L [MBzP] and 0.4 mg/L [BPA])
were assigned a value of half the limit of detection. Metabolite
concentrations were right-skewed and transformed using the nat-
ural logarithm. In analyses in which metabolites were catego-
rized, we adjusted concentrations by specific gravity before
ranking as described previously.6 Consistent with our previous
approach,2 we used a modified Poisson regression to generate
relative risk (RR), and variance estimates for dichotomized out-
comes (ie, child asthma) using the methods of Zou.7 Analyses
were conducted using SPSS 21 (IBM, Armonk, NY). Results
were considered significant at P < .05.
A total of 168 of 292 (57.5%) children had a history of asthma-
related symptoms on repeat questionnaires. Of these, 142 were
evaluated by a study allergist or pulmonologist; 86 were
diagnosed with current asthma and 56 with asthma-related
symptoms but without current asthma. The remaining 124
children had no history of asthma-like symptoms and were
classified as nonasthmatic. A total of 44 of 217 (20%) children
had persistent wheeze, 62 of 292 (21%) had exercise-induced
wheeze, and 98 of 292 (34%) had emergency care visits for
asthma or other respiratory problems.
A significant association between child (ln)BPA concentrations
and respiratory outcomes was observed only among those
children whose mothers had prenatal MBzP concentrations above
but not below the median. For children with prenatal MBzP
concentrations above the median, the RR per log unit increase in
child BPA concentrations was 1.46 (95% CI, 1.14-1.87) for child
current asthma; 1.89 (95% CI, 1.29-2.78) for persistent wheeze;
1.67 (95% CI, 1.17-2.40) for exercise-induced wheeze; and 1.47
(95% CI, 1.13-1.89) for emergency care visits. The multiplicative
interaction between child (ln)BPA and higher versus lower
prenatal MBzP was significant for asthma (P 5 .001) but not
for other outcomes (Fig 1).
Table I presents associations between asthma and wheeze-
related outcomes among children with both prenatal MBzP and
child BPA concentrataions above the median compared with chil-
dren with one or bothmeasurements below the median. Therewas
a highly significant increase in RR for all these outcomes among
children with both prenatal MBzP and child BPA above the me-
dian. In contrast, there was no increase in RR if only one of the
endocrine-disrupting chemicals but not both were above the me-
dian (P values ranged from 0.12 to 0.94, data not shown). There
were no significant interactions between (1) prenatal BPA and
either prenatal MBzP or MnBP concentrations or (2) prenatal
MnBP and child BPA concentations on the risk of child asthma,
frequent wheeze, exercised-induced wheeze, or emergency care
visits (data not shown).
Using 2 analytic approaches, we found a novel and significant
association between child BPA and risk of child asthma and other
wheeze-related symptoms among inner-city children whose
mothers had higher but not lower prenatal measures of exposures
to BBzP. These findings suggest the possibility of a ‘‘multihit’’
model such that higher prenatal BBzP exposures may render the
child more susceptible to adverse effects of BPA on the airways1
FIG 1. Association between child (ln)BPA concentrations by strata of higher versus lower prenatal MBzP
(above and below median) and child asthma (A), exercise-induced wheeze (B), persistent wheeze (C), and
emergency care vists (D). Models controlled for maternal asthma, household smoke exposure, maternal
prenatal BPA, maternal prenatal specific gravity, maternal prenatal demoralization, child age at asthma
diagnosis or classification as nonasthmatic (Fig 1, A), and child sex (Fig 1, B-D). Mutiplicative interactions
between postnatal (ln)BPA concentrations and higher versus lower prenatal MBzP were also evaluated
for each outcome (Fig 1, A-D). *P < .01 and **P <_ .001.
TABLE I. Asthma-related outcomes among children with both
maternal prenatal MBzP and child BPA above the median versus
one or both below the median







wheeze (n 5 292)
Emergency care
visits (n 5 292)
1.67 (1.25-2.23)* 2.02 (1.22-3.35) 1.76 (1.13-2.72) 1.71 (1.25-2.34)*
Models controlled for maternal asthma, household smoke exposure, prenatal BPA,
maternal prenatal specific gravity, maternal prenatal demoralization, child age (at the
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hypothesis need to be evaluated and results require replication,
findings are of concern given that exposures to these compounds
are ubiquitous in the United States and other countries.
Robin M. Whyatt, DrPHa
Andrew G. Rundle, DrPHa,b
Matthew S. Perzanowski, PhDa
Allan C. Just, PhDc
Kathleen M. Donohue, MD, MSa,d
Antonia M. Calafat, PhDe
Lori Hoepner, MPHa
Frederica P. Perera, DrPH, PhDa
Rachel L. Miller, MDa,d,f
From athe Department of Environmental Health Sciences, Columbia Center for Chil-
dren’s Environmental Health, Mailman School of Public Health, ColumbiaUniversity, New York, NY; bthe Department of Epidemiology, Mailman School of
Public Health, Columbia University, New York, NY; cthe Department of Environ-
mental Health, Harvard School of Public Health, Boston, Mass; dthe Division of Pul-
monary, Allergy, and Critical Care, Department of Medicine, Columbia University
College of Physicians and Surgeons, New York, NY; ethe National Center for Envi-
ronmental Health, Centers for Disease Control and Prevention, Atlanta, Ga; and
fthe Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics,
Columbia University, College of Physician and Surgeons, New York, NY. E-mail:
rmw5@columbia.edu.
This study was supported by the National Institute of Environmental Health
Sciences (NIEHS) (grant nos. R01ES014393, RC2ES018784, R01ES13163, and
R01ES08977 and NIEHS/EPA P01 ES09600/RD 83214101 and P30ES009089);
the John and Wendy Neu Family Foundation; the Blanchette Hooker Rockefeller
Fund; the New York Community Trust; and the Millstream Fund. The findings ex-
pressed in this article are the opinions of the authors and do not necessarily reflect
the official position of the Centers for Disease Control and Prevention.
Disclosure of potential conflict of interest: This study was funded by the National Insti-
tutes of Health (NIH) (R01ES014393, RC2ES018784, R01ES13163, R01ES08977,
P01 ES09600, and P30ES009089) and the Environmental Protection Agency (RD
83214101). L. Hoepner’s institution has received grants from the National Institute
of Environmental Health Sciences (NIEHS) (R01ES014393, RC2ES018784,
R01ES13163, R01ES08977, P01ES09600, R01ES013543, and R01ES014400) and
the Environmental Protection Agency (RD83450901); she has received consultancy
fees from Transcendent International. R. L. Miller and her institution have received
funding from the National Institute of Environmental Health Sciences
(R01ES014393, RC2ES018784, R01ES13163, R01ES08977, and P01ES09600) and
the Environmental Protection Agency (RD83214101). M. S. Perzanowski has
received or has grants pending from the National Institute of Environmental Health
Sciences (R014400), the Centers for Disease Control and Prevention (CDC-TP-
13001), and the Department of Housing and Urban Development (NYHHU003,
NYHHU0021); and has received support for travel and other meeting-related ex-
penses from ThermoFisher. R. M. Whyatt has received funding from National Insti-
tute of Environmental Health Sciences (R01ES021482, R01ES013543,
R01ES014393, RC2ES018784) and the Environmental Protection Agency
(RD83214101). K. M. Donohue has received support from the National Institute of
Environmental Health Sciences (RC2ES0187894), the National Heart, Lung and
Blood Institute (HHSN268200625233C, N01HC95161), and the ALPHA Foundation
(CU110766). F. P. Perera and her institution have received funding from the National
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
LETTER TO THE EDITOR 3Institute of Environmental Health Sciences (P01ES09600, P30ES009089), the Envi-
ronmental Protection Agency (RD83214101), the John and Wendy Neu Family Foun-
dation, the Blanchette Hooker Rockefeller Fund, the New York Community Trust,
and the Millstream Fund. A. Just received support the National Institute of Environ-
mental Health (R01ES014393, T32ES007069, K99ES023450). A. G. Rundle is a
member of the board of EHE International. The rest of the authors declare that
they have no relevant conflicts of interest.REFERENCES
1. Donohue KM, Miller RL, Perzanowski MS, Just AC, Hoepner LA, Arunajadai S,
et al. Prenatal and postnatal bisphenol A exposure and asthma development among
inner-city children. J Allergy Clin Immunol 2013;131:736-42.
2. Whyatt RM, Perzanowski MS, Just AC, Rundle AG, Donohue KM, Calafat AM,
et al. Asthma in inner-city children at 5-11 years of age and prenatal exposure
to phthalates: the Columbia Center for Children’s Environmental Health. Environ
Health Perspect. Sept 17, 2014 [E-pub ahead of print].3. Perera F, Viswanathan S, Whyatt R, Tang D, Miller RL, Rauh V. Children’s envi-
ronmental health research–highlights from the Columbia Center for Children’s
Environmental Health. Ann N Y Acad Sci 2006;1076:15-28.
4. Kato K, Silva MJ, Needham LL, Calafat AM. Determination of 16 phthalate metab-
olites in urine using automated sample preparation and on-line preconcentration/
high-performance liquid chromatography/tandem mass spectrometry. Anal Chem
2005;77:2985-91.
5. Ye X, Kuklenyik Z, Needham LL, Calafat AM. Automated on-line
column-switching HPLC-MS/MS method with peak focusing for the deter-
mination of nine environmental phenols in urine. Anal Chem 2005;77:
5407-13.
6. Hauser R, Meeker JD, Park S, Silva MJ, Calafat AM. Temporal variability of
urinary phthalate metabolite levels in men of reproductive age. Environ Health
Perspect 2004;112:1734-40.
7. Zou GA. modified Poisson regression approach to prospective studies with binary
data. Am J Epidemiol 2004;159:702-6.
http://dx.doi.org/10.1016/j.jaci.2014.07.027
METHODS
Eighteen- to 35-year-old women who self-identified as African American
or Dominican were enrolled through prenatal clinics at Harlem Hospital and
New York Presbyterian Hospital. Women were excluded if they reported
active smoking or use of other tobacco products or illicit drugs; had diabetes,
hypertension, or knownHIV; had their first prenatal visit after the 20thweek of
gestation; or had resided in the study area for less than 1 year before
pregnancy. Family history of asthma was not a required inclusion criterion.
Study subjects’ characteristics are presented in Table E1. The 292 subjects did
not differ significantly from the remaining 435 subjects in the Columbia Cen-
ter for Children’s Environmental Health cohort by race/ethnicity, maternal
prenatal marital status and education level, household income, prenatal and
postnatal tobacco smoke, or maternal history of asthma (all P values >_ .16).
All participants provided written informed consent, children aged 7 years
and older provided assent, and the institutional review boards at the Columbia
UniversityMedical Center and the Centers for Disease Control and Prevention
approved the study.
Variables assessed as potential confounders were selected on the basis of
our previous analyses of prenatal MBzP and postnatal BPA as described
earlierE1,E2 and were retained in the models if they were significant (P < .05)
and/or their inclusion in the model resulted in more than 10% change in pre-
dictor variables. The variables assessed as potential confounders included
maternal age, maternal education, maternal history of asthma, race/ethnicity,
household smoke exposure (from others during pregnancy because the cohort
was restricted to nonsmoking pregnant women at enrollment and from the
mother and/or others during childhood because some mothers began smoking
after delivery), number of previous live births, breast-feeding history, maternal
prenatal BPA concentrations, child age at asthma diagnosis or classification as
nonasthmatic, child sex, and child bodymass index. Maternal prenatal demor-
alization (measured by using a 27-item Psychiatric Epidemiology Research
Instrument-Demoralization ScaleE3) was also assessed because it has been
previously associated with wheeze among children in the cohort.E4 Prenatal
and postnatal urinary specific gravity concentrations were included in models
to control for urinary dilution.We did not collect a validated history of all child
viral illnesses from cohort subjects by questionnaire because we did not
believe that we could do so reliably at the onset of the study. Therefore, we
were not able to determine whether child viral illnesses were potential con-
founders. Child postnatal MBzP and MnBP concentrations were not
controlled because they were not associated with any of the outcomes (all P
values >_ .4) and inclusion did not alter results over those presented here.
The cohort was predominantly full-term (97% >_ 37 weeks’ gestation) and
neither gestational age nor birth weight was a confounder.
REFERENCES
E1. Donohue KM, Miller RL, Perzanowski MS, Just AC, Hoepner LA, Arunajadai S,
et al. Prenatal and postnatal bisphenol A exposure and asthma development
among inner-city children. J Allergy Clin Immunol 2013;131:736-42.
E2. Whyatt RM, Perzanowski MS, Just AC, Rundle AG, Donohue KM, Calafat AM,
et al. Asthma in inner-city children at 5-11 years of age and prenatal exposure to
phthalates: the Columbia Center for Children’s Environmental Health. Environ
Health Perspect Sept 17, 2014 [E-pub ahead of print].
E3. Dohrenwend BS, Krasnoff L, Askenasy AR, Dohrenwend BP. Exemplification of
a method for scaling life events: the Peri Life Events Scale. J Health Soc Behav
1978;19:205-29.
E4. Reyes M, Perzanowski MS, Whyatt RM, Kelvin EA, Rundle AG, Diaz DM, et al.
Relationship between maternal demoralization, wheeze, and immunoglobulin E
among inner-city children. Ann Allergy Asthma Immunol 2011;107:42-9.e41.
J ALLERGY CLIN IMMUNOL
nnn 2014
3.e1 LETTER TO THE EDITOR
TABLE E1. Maternal and child characteristics (n 5 292)
Maternal age (y), mean 6 SD 25.3 6 4.8
Maternal asthma, n (%) 71 (24.3)
Maternal ethnicity, n (%)
Dominican 189 (64.7)
African American 103 (35.3)
Maternal education, n (%)
<High school 106 (36.3)
High school or general educational development 106 (36.3)
>High school 80 (27.4)
Maternal marital status, n (%)
Never married 194 (66.4)
Married* 84 (28.8)
Separated, widowed, divorced 14 (4.8)
Child age and sex
Child age (y), mean 6 SD 8.2 6 1.9
Child sex (female), n (%) 157 (53.8)
Household tobacco smoke exposure
Others in the home prenatally 93 (31.8)
Maternal and others early to mid-childhood 129 (44.2)
Maternal MBzP (ng/mL), geometric mean (95% CI) 13.2 (11.4-15.5)
Child BPA (ng/mL),§ geometric mean (95% CI) 3.9 (3.5-4.3)
*Includes women living with a partner for more than 7 years.
Age at asthma diagnosis for those diagnosed with current asthma and at the last
negative screen for asthmalike symptoms for those classified as nonasthmatic.
The study excluded active smoking women during pregnancy.
§Mean concentrations in samples of children aged 3 to 7 years, except children (n5 10)
missing respiratory questionnaire data after age 6 years for whom the mean BPAwas
calculated for ages 3 to 5 years.
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